

June 30, 2026

To,  
 National Stock Exchange of India Limited  
 Exchange Plaza  
 Bandra Kurla Complex,  
 Bandra (E), Mumbai - 400051  
**(SYMBOL: THYROCARE)**

BSE Limited  
 Phiroze Jeejeeboy Towers  
 Dalal Street,  
 Mumbai- 400001  
**(SCRIP CODE: 539871)**

**Sub : Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')**

Dear Sir / Madam,

We wish to inform you that the Members of Thyrocare Technologies Limited (“the Company”), at the 26<sup>th</sup> Annual General Meeting (“AGM”) of the Company held on Tuesday, June 30, 2026, at the Corporate Office of the Company situated at D/37-3, TTC Industrial Area, MIDC, Turbhe, Navi Mumbai – 400703, have duly approved the amendment to the Memorandum of Association (“MOA”) of the Company, the details whereof are set out in the table below:

Particulars	Erstwhile Clauses	Amended clauses
Substitution of heading of Clause III(A)	MAIN OBJECTS OF THE COMPANY TO BE PURSUED BY THE COMPANY ON ITS INCORPORATION	THE OBJECTS TO BE PURSUED BY THE COMPANY ARE
Addition of Sub clause 1B under Clause III(A)(1)	-	1B To carry on the business of establishing, setting up, acquiring, operating, managing or administering diagnostic facilities (including home collection), including but not limited to, clinical laboratories, radiology and pathology centres, collection centres, hospitals, clinics, polyclinics, research and healthcare facilities, and to provide healthcare and diagnostic services including pathological, radiological, biochemical, microbiological, immunological, genetic, cardiological and other medical investigations and testing services, and to undertake collection, handling, storage, transportation, processing and analysis of human, animal, plant, food, water, soil and other samples, tissues, body fluids, blood and allied materials for diagnostic, therapeutic, research or other purposes, in India or abroad, under its own brand or otherwise, including through online or digital platforms; and to develop, operate and manage healthcare, diagnostic and data-driven digital platforms, applications and portals; and to undertake teaching, training and imparting practical and theoretical knowledge in diagnostics, pathology, healthcare and allied fields; and further to manufacture, produce, assemble, process, procure, purchase, import, export, stock, distribute, market,

**Tests you can trust**

		sell, resell, lease, hire or otherwise deal in medical, diagnostic, healthcare, pharmaceutical, surgical, wellness equipment, devices, instruments, consumables, merchandise and allied products, including point of care devices, and to carry on such activities either on its own or in collaboration with third parties, partners, franchisees or service providers in India or abroad.
Substitution of heading of Clause III(B)	Object incidental or ancillary to the attainment of main objects:	Matters which are necessary for furtherance of the objects specified in Clause III(A) are:
Deletion of header of Clause III(C) i.e., "Other Objects"	Other Objects:	Deleted in line with the Companies Act, 2013, as such clauses are now covered under Clause III(B)
Substitution of Clause IV	The liability of the members is limited	The Liability of members is limited and this liability is limited to the amount unpaid, if any, on the shares held by them.
Statutory alignment	References to Companies Act, 1956	To be replaced with corresponding provisions of the Companies Act, 2013 along with necessary consequential changes

This disclosure is also being made available on the website of the Company at <https://investor.thyrocare.com/>.

The above is submitted for your kind information and necessary records.

Yours faithfully,  
For **Thyrocare Technologies Limited**



**Brijesh Kumar**  
Company Secretary and Compliance Officer